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Background: This study aimed to investigate the development of opioid tolerance in patients receiving long-term
methadone maintenance treatment (MMT).
Methods: A region-wide cross-sectional study was performed focusing on dosage and duration of treatment.
Differences between racemic methadone and levomethadone were examined. All 20 psychiatric hospitals and all
110 outpatient clinics in Berlin licensed to offer MMT were approached in order to reach patients under MMT
fulfilling the DSM IV criteria of opiate dependence. In the study, 720 patients treated with racemic methadone
or levomethadone gave information on the dosage of treatment. Out of these, 679 patients indicated the
duration of MMT.
Results: Treatment with racemic methadone was reported for 370 patients (54.5 %), with levomethadone for
309 patients (45.5 %). Mean duration of MMT was 7.5 years. We found a significant correlation between dosage and
duration of treatment, both in a conjoint analysis for the two substances racemic methadone and levomethadone and
for each substance separately. These effects remained significant when only patients receiving MMT for 1 year
or longer were considered, indicating proceeding tolerance development in long-term treatment. When correlations
were compared between racemic methadone and levomethadone, no significant difference was found.
Conclusions: Our data show a tolerance development under long-term treatment with both racemic methadone and
levomethadone. Tolerance development did not differ significantly between the two substances.
Keywords: Opioid, Tolerance, Long-term, Maintenance treatmentBackground
Methadone is currently the preferred drug of choice for
the treatment of opioid dependence in many countries
[1]. Methadone maintenance treatment (MMT) has
been implemented to increase survival and stabilize
patients, in order to enable them to reach opioid ab-
stinence [2–4]. The advantages of MMT in opioid-
dependent patients on mental and physical health and
social integration have been described by reducing
morbidity and mortality [1, 5–9], improving employ-
ment rates and reducing criminal activity [10–12].* Correspondence: stefan.gutwinski@charite.de
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(http://creativecommons.org/publicdomain/zeMethadone is a synthetic opioid and was initially
launched as an analgesic in 1939 [13]. It was intro-
duced for the treatment of opioid dependence by
Dole, Nyswander, and Kreek in 1964 [13, 14]. The long
duration of methadone leads to a “narcotic blockade” and
eliminates withdrawal symptoms for up to 36 h. Given in
high doses, it reduces craving for heroin and blocks the
effect of injected heroin, thereby freeing the patient from
the daily cycle of seeking out, buying, and consuming
heroin [1, 13–16].
Methadone has an asymmetric carbon atom result-
ing in two enantiomeric forms, the D- and L-isomers
[17, 18]. The L-isomer has a 10 times higher affinity
for the μ-opioid receptor than the D-isomer. Bothicle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Gutwinski et al. Harm Reduction Journal  (2016) 13:7 Page 2 of 6racemic methadone (D-, L-methadone) and levometha-
done (isolated L-methadone) are clinically used in all
countries of the European Union and several countries
worldwide [17, 19].
One potential problem of treatment with opioid
agonists is the development of tolerance [20–22]. The
effect of tolerance has been described for methadone
during short treatment intervals of analgesia but
seems to be reduced compared with other opioids,
such as morphine, showing sometimes more than a
10-fold increase in dosage [18, 23]. It has been hy-
pothesized that methadone’s ability to efficiently
internalize the μ-opioid receptor and to exhibit an
NMDA receptor antagonism may contribute to re-
duced opioid tolerance development compared with
opioids such as morphine and oxycodone [18]. This
antagonistic effect on the NMDA receptor is associ-
ated with both isomers of methadone. However, one
could assume that the development of opioid toler-
ance is particularly attenuated under treatment with
racemic methadone compared to levomethadone. That
is, the D-enantiomer exhibits an antagonistic effect
on NMDA receptors, but only a minimum opioid
effect, resulting in a stronger NMDA-antagonistic effect
per equivalence dose [24–27]. This would result in
reduced tolerance development in racemic methadone
compared to levomethadone.
The development of tolerance is of clinical relevance
because it results in loss of efficacy of opioids and conse-
quently in need of an increase of dosage [20–22]. To our
knowledge, tolerance of methadone has not been exam-
ined over a long treatment period or in patients with
opioid dependence in MMT. Additionally, differences of
tolerance between racemic methadone and levometha-
done have not been examined in opioid-dependent
patients.
To address these issues, we performed a region-wide
cross-sectional study in opioid-dependent patients in
MMT in Berlin, Germany. To study potential tolerance
development and differences between methadone and
levomethadone on tolerance development, we collected
data on dosage and duration of MMT in patients receiv-
ing either methadone or levomethadone.
Firstly, we hypothesized that long-term methadone
treatment in opioid-dependent patients results in a
tolerance development. Secondly, we hypothesized that
treatment with racemic methadone compared to levo-
methadone leads to a reduced tolerance development.
Methods
The study was approved by the local ethics of the
Charité, Universitätsmedizin Berlin. In our survey, 720
patients participated who were treated with racemic
methadone or levomethadone and gave informationon the dosage of treatment. Out of these, 679 patients
indicated the duration of MMT.
The survey was performed from May to October 2011.
All 20 hospitals and 110 practices in Berlin licensed to
offer MMT were approached in order to reach patients
under MMT fulfilling the DSM IV criteria of opioid de-
pendence. Ten psychiatric hospitals and 47 practices
participated in the study, 29 practices reported to have
the license, but had stopped offering MMT, and 34 prac-
tices and 10 hospitals declined participation. The partici-
pating hospitals and practices were located in 10 out of
the 12 districts of Berlin. In Berlin, 5032 patients were
registered to receive substances of opioid maintenance
treatment.
Patients were informed about the questionnaire both
orally and in writing. The questionnaire was completed
anonymously, without the help of staff, and collected in
a sealed box.
Measurement
Data were collected on substance of treatment, age, sex,
education, duration of MMT (treatment duration with-
out interruptions), duration of dependence, continued
use of illegal drugs despite MMT, dosage, imprisonment,
withdrawal treatment in the past, comorbid psychiatric
disorders, and chronic infection. Additionally, the ques-
tionnaire involved questions on side effects, frequency of
outpatient treatment, and valuation of maintenance
treatment. Different types of questions were used:
grouping questions were used to collect age and dur-
ation of opioid dependence in order to maintain profes-
sional secrecy. Dosage of substitute and duration of
MMT and school education were asked using open
questions. All other items contained single or multiple-
choice questions. The questionnaire was designed for
this study.
Survey data concerning side effects, take-home treat-
ment, and valuation of treatment have been previously
published [28–31]. Anonymity of data was part of the
ethical agreement.
Statistical analysis
Data was analyzed using PASW Statistics 20 employing
chi-square and t test. Correlation analyses were per-
formed by using partial correlations with the covariate
sex. Comparison of correlation was performed via the
Fisher z-transformation.
Results
A total of 679 patients reported the type of substance,
dosage, and duration of MMT. Out of these, 370
patients (54.5 %) reported treatment with racemic
methadone and 309 (45.5 %) with levomethadone. The
mean dosage of methadone (mean dosage of racemic
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equivalent) was 94.1 mg per day (standard deviation
(SD) 43.8). Mean dosage of methadone of patients
treated for 1 year or less (number of patients (N) 51)
was 81.6 mg per day (SD 38.3), and patients treated for
more than 20 years (N 26) reported a dosage of
125.4 mg (SD 42.3). This is an increase of dosage by a
factor of 1.5.
Patients recruited in hospital or practices did not differ
concerning mean dosage of methadone dose equivalent
(hospital 89.9 mg, SD 38.1; practices 94.5 mg, SD 44.8;
p = 0.406, T = 0.8).
The mean duration of MMT of the 679 included pa-
tients was 7.5 years (SD 5.9), with a minimum duration
of 1 month and a maximum duration of 30 years.
Out of the 679 patients, 628 were 1 year or longer in
MMT. Out of these, 339 patients (54.0 %) reported
treatment with racemic methadone and 289 (46.0 %)
with levomethadone.
Clinical data
To characterize patients treated with racemic metha-
done in comparison to those receiving levomethadone,
these two groups were compared with regard to age, sex,
years of education, years of MMT, years of dependency,
continued use of illegal substances, continued use of
multiple illegal substances, mean dosage of methadone
dose equivalent, imprisonment, withdrawal treatment in
the past, comorbid psychiatric disorders, and chronic
infection (see Table 1). These analyses revealed that
patients treated with racemic methadone were signifi-
cantly more often male (75.3 %) compared to patients
treated with levomethadone (65.7 %) (p = 0.006). Pa-
tients treated with levomethadone were significantly
longer in MMT (8.3 years) compared to patients with
racemic methadone (6.8 years) (p = 0.002) and also re-
ceived significantly higher dosages of methadone
equivalent (99.1 mg) compared to patients with ra-
cemic methadone (90.0 mg) (p = 0.007). We did not
find statistically significant differences between both
groups for other factors (see Table 1).
Correlation analyses
In a first step, dose equivalents were considered con-
jointly for racemic methadone and levomethadone. This
analysis revealed a significant correlation between dos-
age and duration of treatment (p = 0.000008; R = 0.171).
Specifically, higher dosages were found in patients indicat-
ing a longer duration of MMT. In a second step, each sub-
stance was examined separately. This analysis revealed a
significant correlation between dosage of racemic metha-
done and duration of treatment (p = 0.001; R = 0.171) as
well as between dosage of levomethadone and duration of
treatment (p = 0.006; R = 0.158). This correlation remainedsignificant, when only patients receiving MMT for 1 year
or longer were considered (p = 0.00008, R = 0.157 for con-
joint analysis; p = 0.007, R = 0.148 for racemic methadone;
p = 0.007, R = 0.157 for levomethadone).Fisher z-transformation
Correlations between dosage and duration of treatment
were compared between racemic methadone and levo-
methadone using the Fisher z-transformation. This com-
parison revealed no significant difference (p = 0.86; z =
0.17). Moreover, no significant difference between sub-
stances was found when only patients receiving MMT
for 1 year or longer were considered (p = 0.91; z = 0.1).Discussion
The data of our study show a significant correlation be-
tween duration of treatment and dosage for both sub-
stances racemic methadone and levomethadone. Longer
duration of treatment was associated with higher dos-
ages, which can be interpreted as a tolerance develop-
ment. This correlation remained significant when only
patients receiving MMT for 1 year or longer were con-
sidered. Thus, even after early adjustment of dosage in
the first year, there is a gradual increase of dosage over
time, which can be interpreted as a long-term tolerance
development.
In our data, we found a 1.5-fold increase of dosage
over 20 years of MMT. The majority of participants in
our study were long-term MMT patients, some with up
to 30 years of treatment. Our data may be of clinical
relevance especially for patients in long-term treatment.
That is, one could assume that the gradual loss of effi-
cacy of methadone may require a successive increase of
dosage to maintain the beneficial effects of MMT. Our
results on long-term treatment add to other studies of
short treatment intervals, showing that tolerance devel-
opment of methadone seems to be reduced compared
with other opioids such as morphine [18, 23].
Our data show significant correlations between duration
of treatment and dosage, for both substances racemic
methadone and levomethadone. These correlations did
not differ significantly between these substances, indicat-
ing that tolerance development is not dependent on the
type of substance. Although we can only speculate on this
finding, it may be that the NMDA antagonism has
only minor impact on the long-term development of
tolerance, or is less relevant compared to other mech-
anisms influencing tolerance, such as the internaliza-
tion of the μ-receptor.
Although the current study comprised more than 600
patients, it may be that the sample was too small to de-
tect a difference in tolerance development between two
substances.
Table 1 Clinical data
Clinical dataa Substance Statistic
Methadone Levomethadone p value
(N = 370) (N = 309)
Age (years)
18–20 6 (1.6) 1 (0.3) 0.474c; Χ = 0.54
21–30 84 (22.7) 65 (21.0)
31–40 102 (27.6) 87 (28.2)
41–50 135 (36.5) 117 (37.9)
51–60 35 (9.5) 37 (12.0)
61–70 8 (2.2) 2 (0.6)
Sex
Male 275 (75.3) 203 (65.7) 0.006; Χ = 7.5
Female 90 (24.7) 106 (34.3)
Years of education mean ± SD 10.3 ± 1.7 10.4 ± 1.4 0.751; T = −.32
Years of methadone maintenance treatment mean ± SD 6.8 ± 5.6 8.3 ± 6.2 0.002; T = −3.2
Years of dependency
≤1 1 (0.3) 3 (1.1) 1.0b; Χ = 0.007
≥1–3 9 (2.7) 9 (3.2)
≥3–5 25 (7.6) 15 (5.3)
≥5–10 68 (20.6) 39 (13.8)
≥10 227 (68.8) 216 (76.6)
Continued use of illegal drugs despite MMT 226 (63.8) 205 (67.9) 0.285; Χ = 1.2
Continued use of multiple illegal drug despite MMT 82 (23.6) 81 (27.6) 0.275; Χ = 1.3
Methadone dose/methadone equivalent (mg)b mean ± SD 90.0 ± 41.3 99.1 ± 46.9 0.007; T = −2.7
Imprisonment in the past 212 (60.7) 176 (59.1) 0.688; Χ = 1.9
Withdrawal treatment in the past 172 (50.0) 159 (53.5) 0.372; X = 0.8
Comorbid psychiatric disordere 90 (26.4) 99 (33.3) 0.06; X = 3.7
Chronic infection 180 (52.2) 144 (48.2) 0.31; X = 1.0
HIV 18 (5.2) 25 (8.3) 0.117; X = 2.5
Hepatits C 163 (47.2) 124 (41.5) 0.141; X = 2.1
Hepatitis B 25 (7.2) 27 (9.0) 0.407; X = 0.6
Lues 1 (0.3) 2 (0.7) 0.483; X = 0.5
aData shown as N (%) if not otherwise specified. Out of the 679 patients who specified type of substance, dosage, and duration of MMT, some patients did not
gave information concerning further data: 5 concerning gender, 67 concerning duration of dependence, 31 concerning detoxification therapies, 23 concerning
continued use of illegal drugs, 42 concerning continued use of multiple illegal drugs, and 32 concerning imprisonment
bDosage of levomethadone was calculated into equivalent methadone dosage
cChi-square for group ≤30 versus >30 age (years)
dChi-square for group ≤5 versus >5 years of dependency
eMultiple answers were possible. Comorbid psychiatric disorders reported N > 5: depression N = 108; psychotic disorder and schizophrenia N = 13; anxiety disorders
N = 30; personality disorder N = 39; and ADHD N = 10
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allowed us the inclusion of patients with up to 30 years
of MMT. However, the cross-sectional design also
comes with a few limitations: Firstly, it cannot be ruled
out that dosing practice has changed over the past 20 to
30 years. Patients who have been in MMT for a long
time might have received higher initial dosages than
commonly applied these days. On the other hand, just in
the past 10 years, guidelines, for example of theCochrane database, tended to recommend higher dos-
ages to prevent relapse [32, 33]. Hence, one would rather
expect higher dosages in the past years, which would re-
sult in a negative correlation, which we did not find.
Additionally, if it was for this bias, it would be equally
for both substances. Secondly, racemic methadone and
levomethadone differed significantly in duration of treat-
ment and mean dosage. On the other hand, comparison
of tolerance (expressing changes of mean dosage over
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affected by the height and length of the gradient.
Thirdly, the study is based on self-reported data, which
might limit the quality of results concerning concomi-
tant use of illegal substances or comorbid psychiatric
disorders. On the other hand, the survey was performed
anonymously, and there was no reason of not reporting,
e.g., concomitant use of illegal substances. Additionally,
it is very likely that patients answered correctly concern-
ing the data we focused on: type of substance, dosage,
and duration of treatment. Fourthly, we cannot exclude
patients misusing substances of MMT over time, which
might drive increasing dosage. On the other hand, this
misuse might represent the need of higher dosage in
terms of tolerance. However, we cannot exclude that sin-
gle persons received higher dosages without taking
medication, but selling it instead [34].
Nevertheless, long-term randomized prospective trials
are needed to examine the development of methadone
tolerance. Such trials are difficult to carry out due to
high relapse rates and the precondition of blindness of
dosage, which few opioid users would accept.
The mean dosages in our sample were between 90 and
100 mg methadone dose equivalent per day. These dos-
ages are in accordance with the recommended dosages
of a review of the Cochrane Collaboration, showing
higher effectiveness in higher dosages [33]. Patients in
our sample had mean treatment duration of 7.5 years,
and some patients were up to 30 years in MMT. These
long periods of treatment stand both for the effective-
ness of MMT and for a growing number of patients
permanently remaining in MMT programs [30, 35–38].
Conclusions
Our data show an increase of dosage in patients with
methadone and levomethadone, which could be inter-
preted as tolerance development under long-term
MMT. However, tolerance development did not differ
significantly between racemic methadone and levo-
methadone. Our study has some limitations, such as the
cross-sectional design and the self-reported data. None-
theless, our data may be relevant for long-term MMT
patients. When patients and their staff physicians
observe a decrease of opioid efficacy during MMT (e.g.,
relapse, or symptoms of craving), tolerance development
could be a contributing factor.
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